Close Menu

Quartz Bio and the Swiss Institute of Bioinformatics are working together to develop and validate MegaClust, SIB's platform for analyzing flow cytomery data, so that they can use it to provide analysis services to pharmaceutical companies.

The partners want to test whether or not MegaClust, which is comprised of a set of clustering algorithms, can be used to "systematically" assess large quantities of data generated from flow cytometry experiments in clinical trials, Jérôme Wojcik, Quartz Bio's CEO, told BioInform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.